Procaps Group S.A. 9X1.F Stock
Procaps Group S.A. Price Chart
Procaps Group S.A. 9X1.F Financial and Trading Overview
Procaps Group S.A. stock price | 2.22 EUR |
Previous Close | 3.86 EUR |
Open | 3.84 EUR |
Bid | 3.92 EUR x N/A |
Ask | 4.1 EUR x N/A |
Day's Range | 3.84 - 3.84 EUR |
52 Week Range | 3.3 - 8.5 EUR |
Volume | 400 EUR |
Avg. Volume | 10 EUR |
Market Cap | 452.28M EUR |
Beta (5Y Monthly) | 0.080557 |
PE Ratio (TTM) | 12 |
EPS (TTM) | 0.47 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
9X1.F Valuation Measures
Enterprise Value | 653.46M EUR |
Trailing P/E | 12 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.1073097 |
Price/Book (mrq) | 64 |
Enterprise Value/Revenue | 1.6 |
Enterprise Value/EBITDA | 10.257 |
Trading Information
Procaps Group S.A. Stock Price History
Beta (5Y Monthly) | 0.080557 |
52-Week Change | -50.57% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.5 EUR |
52 Week Low | 3.3 EUR |
50-Day Moving Average | 4 EUR |
200-Day Moving Average | 5.05 EUR |
9X1.F Share Statistics
Avg. Volume (3 month) | 10 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 112.82M |
Float | 17.09M |
Short Ratio | N/A |
% Held by Insiders | 84.67% |
% Held by Institutions | 3.31% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 8.00% |
Operating Margin (ttm) | 13.69% |
Gross Margin | 58.39% |
EBITDA Margin | 15.59% |
Management Effectiveness
Return on Assets (ttm) | 7.55% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 408.45M EUR |
Revenue Per Share (ttm) | 4.04 EUR |
Quarterly Revenue Growth (yoy) | -1.70% |
Gross Profit (ttm) | N/A |
EBITDA | 63.71M EUR |
Net Income Avi to Common (ttm) | 32.72M EUR |
Diluted EPS (ttm) | 0.32 |
Quarterly Earnings Growth (yoy) | -59.69% |
Balance Sheet
Total Cash (mrq) | 23.03M EUR |
Total Cash Per Share (mrq) | 0.23 EUR |
Total Debt (mrq) | 285.12M EUR |
Total Debt/Equity (mrq) | 5516.02 EUR |
Current Ratio (mrq) | 1.152 |
Book Value Per Share (mrq) | 0.06 |
Cash Flow Statement
Operating Cash Flow (ttm) | 10.88M EUR |
Levered Free Cash Flow (ttm) | -23095250 EUR |
Profile of Procaps Group S.A.
Country | Germany |
State | N/A |
City | Luxembourg City |
Address | 9 Rue de Bitbourg |
ZIP | 1273 |
Phone | 356 7995 6138 |
Website | https://www.procapsgroup.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 5500 |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Q&A For Procaps Group S.A. Stock
What is a current 9X1.F stock price?
Procaps Group S.A. 9X1.F stock price today per share is 2.22 EUR.
How to purchase Procaps Group S.A. stock?
You can buy 9X1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Procaps Group S.A.?
The stock symbol or ticker of Procaps Group S.A. is 9X1.F.
Which industry does the Procaps Group S.A. company belong to?
The Procaps Group S.A. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Procaps Group S.A. have in circulation?
The max supply of Procaps Group S.A. shares is 131.74M.
What is Procaps Group S.A. Price to Earnings Ratio (PE Ratio)?
Procaps Group S.A. PE Ratio is 4.72340440 now.
What was Procaps Group S.A. earnings per share over the trailing 12 months (TTM)?
Procaps Group S.A. EPS is 0.47 EUR over the trailing 12 months.
Which sector does the Procaps Group S.A. company belong to?
The Procaps Group S.A. sector is Healthcare.